Molecular imaging using 18F-FDG PET/CT and circulating inflammatory and immune indicators to predict pathological response to neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA–IIIB NSCLC
Kaiyue Wang, Xiaohan Wang, Xue Meng, Guodong Zhang, Guoxin Cai
Springer Nature ·
2025-05-10
· DOI 10.1007/s12149-025-02057-0
The publisher did not provide an abstract — full text is available via the link below.
Kaiyue Wang, Xiaohan Wang, Xue Meng, Guodong Zhang, Guoxin Cai. Molecular imaging using 18F-FDG PET/CT and circulating inflammatory and immune indicators to predict pathological response to neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA–IIIB NSCLC. // Annals of Nuclear Medicine. – 2025. – DOI: 10.1007/s12149-025-02057-0. – URL: https://doi.org/10.1007/s12149-025-02057-0
Kaiyue Wang, Xiaohan Wang, Xue Meng, Guodong Zhang, & Guoxin Cai (2025). Molecular imaging using 18F-FDG PET/CT and circulating inflammatory and immune indicators to predict pathological response to neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA–IIIB NSCLC. Annals of Nuclear Medicine. https://doi.org/10.1007/s12149-025-02057-0
Kaiyue Wang, et al. “Molecular imaging using 18F-FDG PET/CT and circulating inflammatory and immune indicators to predict pathological response to neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA–IIIB NSCLC.” Annals of Nuclear Medicine, 2025. doi:10.1007/s12149-025-02057-0.
@article{Wang2025,
title = {Molecular imaging using 18F-FDG PET/CT and circulating inflammatory and immune indicators to predict pathological response to neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA–IIIB NSCLC},
author = {Wang, Kaiyue and Wang, Xiaohan and Meng, Xue and Zhang, Guodong and Cai, Guoxin},
journal = {Annals of Nuclear Medicine},
year = {2025},
doi = {10.1007/s12149-025-02057-0},
url = {https://doi.org/10.1007/s12149-025-02057-0}
}